SAVANNAH, Ga. October 9, 2007 MIT Holding, Inc. (OTCBB: MITD), in collaboration with MEVLABS and Georgia Southern University, have successfully tested prototype designs of the patent pending PROVECTOR. This small dispensable device is designed to stop the development of pathogens and parasites found in mosquitoes that carry deadly diseases such as malaria, dengue fever, and West Nile virus. The PROVECTOR will initially be made available in countries where such diseases are a major threat to the health of the population. MIT intends to distribute the PROVECTOR internationally to licensees through worldwide distribution partnerships.
The PROVECTOR uses visual, olfactory and chemical signals to attract mosquitoes, which ingest anti-malarial and anti-viral treatments that inhibit the development of the pathogens within the mosquito. The two current principal methods of controlling malaria are drug treatment of patients and the application of pesticides, which can both be very expensive, particularly in developing countries. Additionally, increases in drug resistance of the parasite, as well as widespread insecticide resistance in mosquitoes, cause these current methods to be less effective. Preliminary tests of prototypes of the PROVECTOR have indicated a reduction in the dengue viruses and malaria carried by mosquitoes. The Company is continuing to refine its prototypes prior to commercialization.
Dr. Thomas M. Kollars, Jr., Chief Scientific Advisor of MIT Holding and Chief Executive Officer of MEVLABS, commented, The PROVECTOR provides a safe and economical solution to the health threat that mosquitoes carrying infectious disease pose to humans. Malaria currently infects over one hundred million people worldwide and kills at least a million people every year, mostly children. Dengue fever is also currently on the rise worldwide, causing illness in hundreds of thousands of people. Dengue cases have also been reported on the border of the Uni
|Contact: Janet Vasquez|